Contributors: Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS); Università degli Studi di Salerno = University of Salerno (UNISA); University of Ottawa Ottawa; Federal University of Health Sciences of Porto Alegre = Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA); European Society of Cardiology (ESC); University of Karachi; Epidémiologie des Maladies Chroniques en zone tropicale (EpiMaCT); Institut de Recherche pour le Développement (IRD)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-OmégaHealth (ΩHealth); Université de Limoges (UNILIM)-Université de Limoges (UNILIM); Plate forme de bioinformatique et biostatistique (CEBIMER); Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST); Service de cardiologie CHU Limoges; CHU Limoges; Instituto de Investigación Sanitaria del Hospital Clínico San Carlos Madrid, Spain (IdISSC); Antwerp University Hospital Edegem (UZA); Université Catholique de Louvain = Catholic University of Louvain (UCL); Ruhr University Bochum = Ruhr-Universität Bochum (RUB); Università degli studi di Genova = University of Genoa (UniGe); CHU Rouen; Normandie Université (NU); Samsung Medical Center Sungkyunkwan University School of Medicine; Institute Division of Hematology/Oncology; Institute of Cardiology (WARSAW - Cardiology); Institute of Cardiology; Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou; ARN régulateurs bactériens et médecine (BRM); Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes (Biosit : Biologie - Santé - Innovation Technologique); Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Centre Hospitalier Universitaire Sart Tilman (CHU Sart Tilman); Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich (ULiège)-Centre Hospitalier Universitaire de Liège (CHU-Liège); GIGA Institute Université de Liège (GIGA Liège ); Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich (ULiège); Service de cardiologie Pédiatrique Marseille; Hôpital de la Timone CHU - APHM (TIMONE); Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2016), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018), Vifor (2019–2022).
Abstract: International audience ; Aims: Purpose of this study is to compare the clinical course and outcome of patients with recurrent versus first-episode infective endocarditis (IE).Methods: Patients with recurrent and first-episode IE enrolled in the EUROpean ENDOcarditis (EURO-ENDO) registry including 156 centres were identified and compared using propensity score matching. Recurrent IE was classified as relapse when IE occurred ≤6 months after a previous episode or reinfection when IE occurred >6 months after the prior episode.Results: 3106 patients were enrolled: 2839 (91.4%) patients with first-episode IE (mean age 59.4 (±18.1); 68.3% male) and 267 (8.6%) patients with recurrent IE (mean age 58.1 (±17.7); 74.9% male). Among patients with recurrent IE, 13.2% were intravenous drug users (IVDUs), 66.4% had a repaired or replaced valve with the tricuspid valve being more frequently involved compared with patients with first-episode IE (20.3% vs 14.1%; p=0.012). In patients with a first episode of IE, the aortic valve was more frequently involved (45.6% vs 39.5%; p=0.061). Recurrent relapse and reinfection were 20.6% and 79.4%, respectively. Staphylococcus aureus was the microorganism most frequently observed in both groups (p=0.207). There were no differences in in-hospital and post-hospitalisation mortality between recurrent and first-episode IE. In patients with recurrent IE, in-hospital mortality was higher in IVDU patients. Independent predictors of poorer in-hospital and 1-year outcome, including the occurrence of cardiogenic and septic shock, valvular disease severity and failure to undertake surgery when indicated, were similar for recurrent and first-episode IE.Conclusions: In-hospital and 1-year mortality was similar in patients with recurrent and first-episode IE who shared similar predictors of poor outcome.
Processing Request
No Comments.